A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

被引：17
作者：
Li, Jia
Wang, Yulan
Fenwick, Alan
Clayton, T. Andrew
Lau, Yu Y. K.
Legido-Quigley, Cristina
Lindon, John C.
Utzinger, Juerg
Holmes, Elaine
机构：
[1] Univ London Imperial Coll Sci Technol & Med, SORA Div, Dept Biomol Med, London SW7 2AZ, England
[2] Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland
[3] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, London SW7 2AZ, England
[5] Kings Coll London, Pharm Res Div, London SE1 9NH, England
来源：
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2007年 / 45卷 / 02期
关键词：
high-performance liquid chromatography; nuclear magnetic resonance spectroscopy; praziquantel; principal component analysis; quality control; schistosomiasis;
D O I：
10.1016/j.jpba.2007.06.017
中图分类号：
O65 [分析化学];
学科分类号：
070302 ; 081704 ;
摘要：
The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance liquid chromatography-ultraviolet (HPLC-UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of tablets was also examined by means of H-1 nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition analysis by means of principal component analysis. The HPLC-UV results showed that each batch of PZQ tablets contained approximately the required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码：263 / 267
页数：5
相关论文
共 24 条
[1]  
Appleton Chris C., 2001, Trends in Parasitology, V17, P356, DOI 10.1016/S1471-4922(01)02028-1
[2]   Prediction of anti-plasmodial activity of Artemisia annua extracts:: application of 1H NMR spectroscopy and chernometrics [J].
Bailey, NJC ;
Wang, YL ;
Sampson, J ;
Davis, W ;
Whitcombe, I ;
Hylands, PJ ;
Croft, SL ;
Holmes, E .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 35 (01) :117-126
[3]   Multi-component metabolic classification of commercial feverfew preparations via high-field 1H-NMR spectroscopy and chemometrics [J].
Bailey, NJC ;
Sampson, J ;
Hylands, PJ ;
Nicholson, JK ;
Holmes, E .
PLANTA MEDICA, 2002, 68 (08) :734-738
[4]   Isotopic characterisation of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethylamphetamine (ecstasy) [J].
Carter, JF ;
Titterton, EL ;
Murray, M ;
Sleeman, R .
ANALYST, 2002, 127 (06) :830-833
[5]   Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience [J].
Chen, MG .
ACTA TROPICA, 2005, 96 (2-3) :168-176
[6]   Chemotherapy of schistosomiasis: An update [J].
Cioli, D .
PARASITOLOGY TODAY, 1998, 14 (10) :418-422
[7]   Composition analysis of two batches of polysorbate 60 using MS and NMR techniques [J].
Dang, HV ;
Gray, AI ;
Watson, D ;
Bates, CD ;
Scholes, P ;
Eccleston, GM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (05) :1155-1165
[8]  
European Pharmacopeia, 2005, EUR PHARM
[9]   Drugs for the control of parasitic diseases: current status and development in schistosomiasis [J].
Fenwick, A ;
Savioli, L ;
Engels, D ;
Bergquist, NR ;
Todd, MH .
TRENDS IN PARASITOLOGY, 2003, 19 (11) :509-515
[10]   Epidemiology, burden and control of schistosomiasis with particular consideration to past and current treatment trends [J].
Fenwick, Alan ;
Keiser, Jennifer ;
Utzinger, Jurg .
DRUGS OF THE FUTURE, 2006, 31 (05) :413-425
123